Kristen Overton1, Jacqueline Clegg2, Frances Pekin2, James Wood2, Colette McGrath2, Andrew Lloyd3, Jeffrey J Post4. 1. Department of Infectious Diseases, Prince of Wales Hospital, Randwick, 2031, Australia; Population Health, New South Wales Justice Health and Forensic Mental Health Network, Malabar, 2036, Australia; Prince of Wales Clinical School, University of New South Wales, Kensington, 2052, Australia. Electronic address: Kristen.overton@health.nsw.gov.au. 2. Population Health, New South Wales Justice Health and Forensic Mental Health Network, Malabar, 2036, Australia. 3. Department of Infectious Diseases, Prince of Wales Hospital, Randwick, 2031, Australia; Population Health, New South Wales Justice Health and Forensic Mental Health Network, Malabar, 2036, Australia; The Kirby Institute, Viral Immunology Systems Program, Kensington, 2052, Australia. 4. Department of Infectious Diseases, Prince of Wales Hospital, Randwick, 2031, Australia; Population Health, New South Wales Justice Health and Forensic Mental Health Network, Malabar, 2036, Australia; Prince of Wales Clinical School, University of New South Wales, Kensington, 2052, Australia.
Abstract
BACKGROUND: People in prison have been identified as an important population to prioritise for hepatitis C virus (HCV) treatment to achieve HCV elimination goals. We evaluated the efficacy of the New South Wales Justice Health and Forensic Mental Health Network Hepatitis Nurse Led Model of Care during the 12 months following the widespread availability of HCV direct acting antivirals (DAAs) in Australia. METHODS: A retrospective cohort study was conducted of a network of 36 correctional centres across NSW from April 2016 to March 2017, with approximately 13 000 full time inmates. Population Health Nurses conducted initial clinical assessments and confirmatory testing. Patients were referred to a Hepatitis Clinical Nurse Consultant (CNC) for protocol-driven assessment, including transient elastography to assess hepatic fibrosis. The CNC then discussed the case with an Infectious Diseases physician and DAA therapies were prescribed. The total number of patients who commenced and completed treatment, and sustained virological response 12 weeks post treatment completion (SVR 12) were recorded. RESULTS: During the first 12 months of DAA treatment 698 patients were commenced on HCV treatment. Of those who were tested at the 12-week post treatment completion timepoint the per-protocol SVR12 (cure) rate was 92% (396/430), with 34 patients having a detectable viral load. 52 (7%) patients were released to freedom before completing treatment and a further 211 (30%) were released prior to SVR12 assessment. These outcomes indicate an intention-to-treat SVR 12 cure rate of 57% (396/698). There were no differences in demographic or treatment characteristics between those who underwent SVR12 testing and those released prior. CONCLUSIONS: Treatment for HCV can be delivered safely, efficiently and in high numbers in the prison setting using a nurse-led model of care. This will be an important component of the strategy to eliminate HCV infection as a public health concern by 2030.
BACKGROUND:People in prison have been identified as an important population to prioritise for hepatitis C virus (HCV) treatment to achieve HCV elimination goals. We evaluated the efficacy of the New South Wales Justice Health and Forensic Mental Health Network Hepatitis Nurse Led Model of Care during the 12 months following the widespread availability of HCV direct acting antivirals (DAAs) in Australia. METHODS: A retrospective cohort study was conducted of a network of 36 correctional centres across NSW from April 2016 to March 2017, with approximately 13 000 full time inmates. Population Health Nurses conducted initial clinical assessments and confirmatory testing. Patients were referred to a Hepatitis Clinical Nurse Consultant (CNC) for protocol-driven assessment, including transient elastography to assess hepatic fibrosis. The CNC then discussed the case with an Infectious Diseases physician and DAA therapies were prescribed. The total number of patients who commenced and completed treatment, and sustained virological response 12 weeks post treatment completion (SVR 12) were recorded. RESULTS: During the first 12 months of DAA treatment 698 patients were commenced on HCV treatment. Of those who were tested at the 12-week post treatment completion timepoint the per-protocol SVR12 (cure) rate was 92% (396/430), with 34 patients having a detectable viral load. 52 (7%) patients were released to freedom before completing treatment and a further 211 (30%) were released prior to SVR12 assessment. These outcomes indicate an intention-to-treat SVR 12 cure rate of 57% (396/698). There were no differences in demographic or treatment characteristics between those who underwent SVR12 testing and those released prior. CONCLUSIONS: Treatment for HCV can be delivered safely, efficiently and in high numbers in the prison setting using a nurse-led model of care. This will be an important component of the strategy to eliminate HCV infection as a public health concern by 2030.
Authors: Nadine Kronfli; Camille Dussault; Sofia Bartlett; Dennaye Fuchs; Kelly Kaita; Kate Harland; Brandi Martin; Cindy Whitten-Nagle; Joseph Cox Journal: Can Liver J Date: 2021-08-09
Authors: Maria A Corcorran; Natasha Ludwig-Baron; Debbie M Cheng; Dmitry Lioznov; Natalia Gnatienko; Gregory Patts; Kaku So-Armah; Elena Blokhina; Sally Bendiks; Evgeny Krupitsky; Jeffrey H Samet; Judith I Tsui Journal: AIDS Behav Date: 2021-03-17
Authors: Jisoo A Kwon; Georgina M Chambers; Fabio Luciani; Lei Zhang; Shamin Kinathil; Dennis Kim; Hla-Hla Thein; Willings Botha; Sandra Thompson; Andrew Lloyd; Lorraine Yap; Richard T Gray; Tony Butler Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Vito Fiore; Giuseppe De Matteis; Emanuele Pontali; Andrea De Vito; Sandro Panese; Nicholas Geremia; Ivana Maida; Stefania Artioli; Giulio Starnini; Giordano Madeddu; Sergio Babudieri Journal: Front Public Health Date: 2022-10-04
Authors: Timothy Papaluca; Anne Craigie; Lucy McDonald; Amy Edwards; Michael MacIsaac; Jacinta A Holmes; Matthew Jarman; Tanya Lee; Hannah Huang; Andrew Chan; Mark Lai; Vijaya Sundararajan; Joseph S Doyle; Margaret Hellard; Mark Stoove; Jessica Howell; Paul Desmond; David Iser; Alexander J Thompson Journal: PLoS One Date: 2020-11-18 Impact factor: 3.240
Authors: Dana Busschots; Cécile Kremer; Rob Bielen; Özgür M Koc; Leen Heyens; Christian Brixko; Pierre Laukens; Hans Orlent; Pascal Bilaey; Francis De Smet; Geert Hellemans; Gaetan Muyldermans; Luk Van Baelen; Niel Hens; Hans Van Vlierberghe; Geert Robaeys Journal: BMC Infect Dis Date: 2021-07-27 Impact factor: 3.090